Combining therapies targeting multiple toll-like receptors

Details Combining therapies targeting multiple toll-like receptors Combining therapies targeting multiple toll-like receptors

2005-12-12

2011-10-04

Wen, Sharon (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S141100

Reexamination Certificate

active

08029794

ABSTRACT:
The invention relates generally to compositions that contain multiple antibodies, e.g., multiple neutralizing antibodies, that immunospecifically bind to one or more toll-like receptors, e.g., two or more toll-like receptors, and methods of using these compositions in the treatment of inflammatory disorders.

REFERENCES:
patent: 6444206 (2002-09-01), Leturcq
patent: 7271248 (2007-09-01), Hardiman et al.
patent: 7312320 (2007-12-01), Elson
patent: 2005/0265998 (2005-12-01), Elson
patent: 2008/0118514 (2008-05-01), Elson
patent: WO 03/013440 (2003-02-01), None
patent: WO 2005/028509 (2005-03-01), None
patent: WO 2005/047330 (2005-05-01), None
Meng et al. The Journal of Clinical Investigation 2004, 113:1473-1481.
Strom et al. (in Therapeutic Immunology, Austen et al. (Ed.) Blackwell Science, Cambridge MA, 1996; see pp. 451-456).
Akashi et al., “Cutting edge: Cell surface expression and lipopolysaccharide signaling via the Toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages,” J. Immunol., vol. 164(7): 3471-3475 (2000).
Akashi et al., “Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: Higher affinity than that with MD-2 or CD14,” J. Exp. Med., vol. 198(7): 1035-1042 (2003).
Akira et al., “Toll-like receptor signaling,” Nature Reviews Immunology, vol. 4: 491-511 (2004).
Backhed et al, “TLR4-dependent recognition of lipopolysaccharide by epithelial cells requires sCD14,” Cellular Microbiology, vol. 4(8): 493-501 (2002).
Buell et al., “Blockade of human P2X7 receptor function with a monoclonal antibody.” Blood 92: 3521-3528 (1998).
Devaney et al., “Neutrophil elastase up-regulates interleukin via toll-like receptor 4,” FEBS Letters, vol. 544 (1-3): 129-132 (2003).
GenBank Accession No. AAH20690.1 “Lymphocyte antigen 96 [Homo sapiens]”.
GenBank Accession No. BAA78717.1 “MD-2 [Homo sapiens]”.
GenBank Accession No. CAH72619.1 “toll-like receptor 4 [Homo sapiens]”.
GenBank Accession No. CAH72620 “toll-like receptor 4 [Homo sapiens]”.
GenBank Accession No. NP—003254.2 “toll-like receptor 1 [Homo sapiens]”.
GenBank Accession No. NP—003255.2 “toll-like receptor 2 [Homo sapiens]”.
GenBank Accession No. NP—003259.2 “toll-like receptor 5 [Homo sapiens]”.
GenBank Accession No. NP—006059.2 “toll-like receptor 6 [Homo sapiens]”.
GenBank Accession No. NP—056179, “MD-2 protein [Homo sapiens]”.
GenBank Accession No. Q9Y6Y9, “RecName: Full=Lymphocyte antigen 96; AltName: Full=Protein MD-2; AltName: Full=ESPO-1; Flags: Precursor”.
Ishida et al., “Hypoxia diminishes Toll-like Receptor 4 expression through reactive oxygen species generated by mitochondria in endothelial cells,” J. Immunol., vol. 169(4): 2069-2075 (2002).
Johnson et al., “Activation of mammalian Toll-like receptors by endogenous agonists” Crit. Rev. Immunol., 23(1-2):15-44 (2003).
Jones and Bendig, “Rapid PCR-cloning of full-length mouse immunoglobulin variable regions.” Biotechnology (N.Y.), 9: 88-89 (1991).
Kammann et al., “Rapid insertional mutagenesis of DNA by polymerase chain reaction (PCR),” Nucleic Acids Res.. vol. 17: 5404 (1989).
Kawasaki et al., “Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis,” J. Immunol., vol. 170(1): 413-420 (2003).
Kirkland et al., “Analysis of Lipopolysaccharide Binding by CD14,” J. Biol. Chem., vol. 268(33): 24818-24823(1993).
Kolbinger et al., “Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies” Protein Eng. 6, 971-980, 1993).
Lakhani et al., “Toll-like receptor signaling in sepsis” Curr. Opin. Pediatr. 15: 278-282 (2003).
Lenhardt et al., “Activation of innate immunity in the CNS triggersneurodegeneration through a Toll-like receptor 4-dependent pathway,” PNAS, vol. 100(14): 8514-8519 (2003).
Medzhitov et al., Nature, “A human homologue of theDrosophilaToll protein signals activation of adaptive immunity,” vol. 388(6640):394-7 (1997).
Meng et al., “Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes,” J. Clin. Invest., vol. 113: 1473-1481 (2004).
Miyake, “Endotoxin recognition molecules MD-2 and Toll-like Receptor 4 as potential targets for therapeutic intervention of endotoxin shock,” Current Drug Targets: Inflammation and Allergy, vol. 3(3): 291-297 (2004).
Miyake, “Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2,” International Immunopharmacology, vol. 3(1): 1199-128 (2003).
Mizel et al., “Induction of macrophage nitric oxide production by gram-negative flagellin involves signaling via heteromeric toll-like receptor 5/toll-like receptor 4 complexes,” J. Immunol., vol. 170: 6217-3223 (2003).
Nijhuis et al, “Endothelial cells are main producers of Interleukin 8 through Toll-like receptor 2 and 4 signaling during bacterial infection in leukopenic cancer patients,” Clinical and Diagnostic Laboratory Immunology, vol. 10(4): 558-563 (20030.
O'Neill, “Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases” Curr. Opin. Pharmacol. 3: 396-403 (2003).
Ohashi et al., “Cutting Edge: Heat Shock Protein 60 is a Putative Endogenous Ligand of the Tdl-Like Receptor-4 Complex,” J. Immunol., vol. 164: 558-561 (2000).
Okamura et al., “The Extra Domain A of Fibronectin Activates Toll-like Receptor 4,” J. Biol. Chem. vol. 276(13): 10229-10233 (2001).
Pasterkamp et al., “Role of Toll-like Receptor 4 in the initiation and progression of atherosclerotic disease,” Eur. J. Clin. Invest., vol. 34(5): 328-334 (2004).
Pivarcsi et al., “Expression and Function of Toll-like Receptors 2 and 4 in Human Keratinocytes,” International Immunology, vol. 15(6): 721-730 (2003).
Pugin et al., “Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock,” Blood, vol. 104(13): 4071-4079 (2004).
Rock et al., “A family of human receptors structurally related toDrosophilaToll,” Proc. Natl. Acad. Sci. USA, vol. 95: 588-593 (1998).
Santa Cruz Biotechnology, Inc., “TLR (H-80): sc-10741”, catalog page for TLR4 (H-80), a rabbit polyclonal antibody raised against amino acids 242-321 of TLR4 of human origin.
Sato et al., “Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth,” Cancer Res. vol. 53: 851-856 (1993).
Shimazu et al., “MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4,” J. Exp. Med., vol. 189(11): 1777-1782 (1999).
Takeda et al., “Toll-like receptors” Annu. Rev. Immunol., 21: 335-76 (2003).
Uehori et al., “Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced byMycobacterium bovisbacillus Calmette-Guérin peptidoglycan,” Infect. Immun., vol. 71(8): 4238-4249 (2003).
Weingarten et al., “Interactions of lipopolysaccharide with neutrophils in blood via CD14,” J. Leukocyte Biol., vol. 53: 518-524 (1993).
Yang et al., “Cellular events mediated by lipopolysaccharide-stimulated Toll-like receptor 4,” J. Biol. Chem., vol. 275(27): 20861-20866 (2000).

Affiliated with

Also associated with

Rating

Combining therapies targeting multiple toll-like receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combining therapies targeting multiple toll-like receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combining therapies targeting multiple toll-like receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4260184